Montelukast Intermediate Market is Expected to Reach USD 8,715.3 Thousand by 2026, at CAGR of 4.71%.

Introduction

Today, increasing prevalence of respiratory illnesses, such as asthma, is one of the major concerns. In the U.S., over 40% of the population dies due to air pollution, the American Lung Association. Moreover, air pollution in middle and low-income countries has more deteriorating effects on the health following long exposure to bad quality air. In addition, the lack of health management policies also worsens the situation in these areas. Several manufacturers are providing asthma management medication, and governments are also taking initiatives to curb the problem of pollution.

Developing Regions to Cater to a Large Allergic Population

Application of montelukast intermediate in drugs includes asthma, allergic rhinitis, bronchospasm, and urticaria. Asthma segment is leading the market on account of the increasing level of air pollution worldwide. According to  WHO, over 91% of the world’s population resides in low air quality area, and 17% of the deaths occur as a result of acute lower respiratory infection.

By end-user, the market is segmented into biotechnology & pharmaceutical companies, laboratories, and others. Biotechnology & pharmaceutical companies are driving the demand for montelukast intermediate for producing  several asthma drugs.

Air pollution is Rising in Asia Pacific

Asia Pacific is projected to witness significant growth during the forecast period as it is the most polluted region in the world and over 92% of the population is exposed to a high level of air pollution on a daily basis, the UN. Moreover, exposure to a high level of toxic environment poses serious health risks and can lead to severe complications such as asthma and respiratory diseases. For instance, over 4 million people die every year due to pollution. However, intervention from international organizations and government initiatives has improved the condition a bit. For instance, in 2017, a combination inhaler of ICS and long-acting β2-agonist (LABA) was added in the WHO Essential Medicines List for the treatment of asthma. Cipla, a major Indian conglomerate, has recently invested USD 22 million in agreement with Pulmatrix Inc for the development of new asthma drugs.

Competitive Players

1. ORTIN LABORATORIES LIMITED (India)
2. MANUS AKTTEVA (India)
3. P.G.Shah & Co. (India)
4. VIVAN Life Sciences (India)
5. Arch Pharmalabs (India)
6. Admiron Life Sciences Pvt Ltd (India)
7. Zhejiang Tianyu Pharmaceutical Co. Ltd (China)
8. Actis Generics Pvt Ltd. (India).

Recent Developments

• February 2023 - A renowned neurologist at the Karolinska Institute in Sweden and IntelGenx partnered to conduct a clinical trial on patients with Parkinson's disease using Montelukast VersaFilm, the company's proprietary oral thin-film formulation. The multicenter trial was expected to be headed by Parkinson's specialist Per Svenningsson, MD, PhD, and was anticipated to begin in July or September.
• November 2023 - The US health regulator has given Aurobindo Pharma's subsidiary permission to market a generic drug for the treatment of pediatric asthma. The Hyderabad-based pharmaceutical company announced in a regulatory filing that Eugia Pharma Specialities, a wholly-owned subsidiary of the company, received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Budesonide Inhalation Suspension.

Segmentation

1. By Type
   1. GMP
   2. Non-GMP
2. By Applications
   1. Asthma 
   2. Bronchospasm
   3. Allergic Rhinitis
   4. Urticaria
3. By End-User
   1. Pharmaceutical and Biotechnological Companies
   2. Laboratories
   3. Others